Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28560399 | 1.00 | ABCB11 (0.39) | ABCB11KMT2AMEN1THRBNR1I2 | |
| SCHEMBL26301826 | 1.00 | ABCB11 (0.39) | ABCB11KMT2AMEN1THRBNR1I2 | |
| SCHEMBL6139230 | 0.92 | PSEN1 (0.43) | ABCB11KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL28824902 | 0.92 | PSEN1 (0.43) | ABCB11KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL28555501 | 0.91 | LMNA (0.42) | ABCB11KMT2AMEN1CASP1ALDH1A1 | |
| SCHEMBL28566525 | 0.90 | GCKR (0.44) | KMT2AALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL29993001 | 0.86 | KMT2A (0.44) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL23524 | 0.86 | KMT2A (0.44) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL14141639 | 0.86 | KMT2A (0.44) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL5672285 | 0.85 | TDP1 (0.40) | KMT2AMEN1CYP2C19CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894186-B2 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI-SYNTHELABO (FR) | 2005-05-17 | — | — | US | claimed |
| US-11834413-B2 | Antiplatelet drugs and uses thereof | SHANGHAI CUREGENE PHARMACEUTICAL CO LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11834413-B2 | Antiplatelet drugs and uses thereof | SHANGHAI CUREGENE PHARMACEUTICAL CO LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230295089-A1 | ANTIPLATELET DRUGS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-106928251-B | Preparation method of high-purity clopidogrel | 江苏天士力帝益药业有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-105153192-A | Substituted tetrahydrothienopyridine derivative and application thereof | NANJING MAJOR BIOTECHNOLOGY CO LTD | 2015-12-16 | — | — | CN | disclosed |
| US-20110190502-A1 | PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | SANDOZ AG (CH) | 2011-08-04 | — | — | US | disclosed |
| EP-2346879-A1 | A PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | Sandoz AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010046476-A1 | A PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | SANDOZ AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| EP-2168969-A2 | Racemization and Enantiomer Separation of Clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-31 | — | — | EP | disclosed |
| US-7259261-B2 | Racemization and enantiomer separation of clopidogrel | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság (HU) | 2007-08-21 | — | — | US | disclosed |
| EP-1802280-A2 | CLOPIDOGREL COMPOSITIONS | Dr. Reddy's Laboratories Ltd. (IN) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044548-A2 | CLOPIDOGREL COMPOSITIONS | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-27 | — | — | WO | disclosed |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | ENTIRE INTEREST | 2005-03-03 | — | — | US | disclosed |
| EP-1483269-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | Teva Pharmaceutical Industries Limited (IL) | 2004-12-08 | — | — | EP | disclosed |
| US-6800759-B2 | REACTING MIXTURE OF (R) AND (S) CLOPIDOGREL FREE BASE WITH LEVOROTATORY CAMPHORSULFONIC ACID IN C5 TO C12 HYDROCARBON TO PRECIPITATE (S) CLOPIDOGREL CAMPHORSULFONATE, CONVERTING TO FREE BASE, PRECIPITATING CLOPIDOGREL BISULFATE IN SOLVENT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-05 | — | — | US | disclosed |
| US-6737411-B2 | CRYSTALLIZING AS CAMPHOR SULFONATE SALT; CONVERTING PURIFIED MATERIAL BACK TO FREE BASE FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-05-18 | — | — | US | disclosed |
| WO-2004013147-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-05 | — | — | US | disclosed |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICALS USA, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | ABCB11 763/4885KMT2A 3811/4885MEN1 3570/4885 |
| US-20110190502-A1 | PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | SRR, P2RY13, P2RY11 | ABCB11 740/4885KMT2A 3925/4885MEN1 3419/4885 |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | SRR, TBXA2R, PTGIR | ABCB11 763/4885KMT2A 3811/4885MEN1 3570/4885 |
| US-11834413-B2 | Antiplatelet drugs and uses thereof | PFKP, GP6, PF4 | ABCB11 847/4885KMT2A 4857/4885MEN1 2835/4885 |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | ABCB11 763/4885KMT2A 3811/4885MEN1 3570/4885 |
| US-20230295089-A1 | ANTIPLATELET DRUGS AND USES THEREOF | PFKP, GP6, PF4 | ABCB11 847/4885KMT2A 4857/4885MEN1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.